Longer-term prospective and randomized studies are needed to confirm the durability of weight loss, clarify differential metabolic effects, and evaluate long-term cardiovascular and hepatic outcomes in treatment-nave populations
Covered products are Wegovy (semaglutide), Foundayo (orforglipron), and the Zepbound KwikPen (tirzepatide)
2, 40 However, the majority of the patients in this study did not have any identifiable genetic causes for their MD
In addition, the following symptoms may indicate a medical emergency and require immediate evaluation: Sudden severe pain in the lower back, abdomen, or legs Severe vomiting, diarrhea, or dehydration Very low blood pressure or loss of consciousness These are not features of typical Adrenal Fatigue
Plus, Wegovy may lead to less weight loss than Zepbound